In an adult with insomnia (difficulty falling or staying asleep) who has comorbid depression or anxiety and has already tried sleep‑hygiene measures, can low‑dose mirtazapine be used, and what are the appropriate dosing and safety considerations?

Low-Dose Mirtazapine for Insomnia in Adults with Comorbid Depression or Anxiety

Low-dose mirtazapine (7.5–15 mg at bedtime) is an appropriate third-line pharmacologic option for insomnia in adults with comorbid depression or anxiety, but only after first-line benzodiazepine-receptor agonists (BzRAs) or ramelteon have failed, and always alongside Cognitive Behavioral Therapy for Insomnia (CBT-I). 1

Treatment Algorithm: When to Use Mirtazapine

Step 1: Initiate CBT-I Immediately (Mandatory First-Line)

• All adults with chronic insomnia must receive CBT-I before or concurrently with any medication, as it provides superior long-term efficacy with sustained benefits after drug discontinuation. 1
• CBT-I includes stimulus control (use bed only for sleep, leave bed if unable to sleep within 20 minutes), sleep restriction (limit time in bed to actual sleep time + 30 minutes), relaxation techniques, and cognitive restructuring of maladaptive sleep beliefs. 1
• Sleep-hygiene education alone is insufficient; it must be integrated into comprehensive CBT-I with stimulus control and sleep restriction components. 1

Step 2: First-Line Pharmacotherapy (If CBT-I Insufficient After 4–8 Weeks)

• For sleep-onset insomnia: zaleplon 10 mg, ramelteon 8 mg, or zolpidem 10 mg (5 mg if age ≥65 years). 1
• For sleep-maintenance insomnia: low-dose doxepin 3–6 mg (reduces wake after sleep onset by 22–23 minutes with minimal anticholinergic effects and no abuse potential) or suvorexant 10 mg. 1
• For combined sleep-onset and maintenance: eszopiclone 2–3 mg (1 mg if age ≥65 years). 1

Step 3: Second-Line – Switch Within Same Class

• If the initial first-line agent fails after 1–2 weeks, switch to an alternative BzRA or orexin antagonist based on the predominant symptom pattern. 1

Step 4: Third-Line – Sedating Antidepressants (Mirtazapine)

• Mirtazapine is positioned as a third-line option specifically when comorbid depression or anxiety is present and first-line agents have failed. 1, 2
• This positioning reflects guideline consensus that sedating antidepressants are reserved for patients who simultaneously require treatment of mood disorders alongside insomnia. 1

Mirtazapine Dosing and Pharmacodynamics

Starting Dose and Titration

• Initiate mirtazapine at 7.5 mg at bedtime; this low dose provides strong sedation through histamine H₁-receptor antagonism while minimizing noradrenergic activation. 1, 2, 3, 4
• Paradoxically, lower doses (7.5 mg) are more sedating than higher doses because histamine blockade predominates at low doses, whereas noradrenergic effects increase at higher doses. 2, 5
• If sleep improvement is inadequate after 1–2 weeks, titrate to 15 mg at bedtime; the maximum dose for insomnia is 30 mg, though most patients respond to 7.5–15 mg. 1, 2, 4

Efficacy Evidence

• In the MIRAGE trial (2025), the highest-quality placebo-controlled study in older adults (≥65 years), mirtazapine 7.5 mg for 28 days reduced Insomnia Severity Index (ISI) scores by 6.5 points compared to 2.9 points with placebo (p=0.003), demonstrating clinically meaningful improvement. 3
• In the DREAMING trial (2025), mirtazapine 7.5–15 mg in adults aged 18–85 years reduced ISI scores by 6.0 points at 6 weeks compared to placebo (95% CI: -9.0 to -3.1), with 52% achieving clinically relevant improvement (>7-point reduction) versus 14% with placebo. 4
• Mirtazapine significantly improved subjective wake after sleep onset, total sleep time, and sleep efficiency in both trials. 3, 4
• However, the benefit was not sustained beyond 12 weeks in the DREAMING trial, indicating that mirtazapine may be most effective for short-to-intermediate-term use (6–12 weeks). 4

Safety Profile and Adverse Effects

• Mirtazapine exhibits very weak muscarinic anticholinergic activity and minimal cytochrome P450 inhibition, making it safer than tricyclic antidepressants and reducing the risk of drug-drug interactions. 2, 5
• Common adverse effects include transient somnolence (most frequent), hyperphagia, and weight gain, attributed to antihistaminic (H₁) activity at low doses. 2, 5
• Somnolence appears to be less frequent at higher doses (15–30 mg) due to increased noradrenergic activation. 5
• In the MIRAGE trial, 6 participants (20%) in the mirtazapine group discontinued treatment due to adverse events (primarily daytime sedation and dizziness) versus 1 participant (3%) in the placebo group, indicating that tolerability may limit its use in some patients. 3
• No severe adverse events or cardiovascular complications were reported in clinical trials at doses up to 7–22 times the maximum recommended dose. 5

Critical Safety Considerations

Monitoring Requirements

• Reassess after 2–4 weeks to evaluate sleep-onset latency, total sleep time, nocturnal awakenings, daytime functioning, and adverse effects such as weight gain or morning sedation. 1
• Use the lowest effective maintenance dose and consider intermittent dosing or tapering when feasible, especially when combined with CBT-I. 1

Discontinuation Strategy

• When stopping mirtazapine, taper the dose over 10–14 days rather than stopping abruptly to minimize withdrawal effects such as rebound insomnia, increased anxiety, and irritability. 2

Special Population Considerations

• In patients with bipolar disorder, mirtazapine should only be used when the patient is concurrently receiving at least one mood stabilizer (e.g., lithium, valproate) to prevent mood destabilization or manic episodes. 2
• Monitor for early signs of mood destabilization (decreased need for sleep, increased energy, racing thoughts, irritability) during the first 4–8 weeks. 2

Medications Explicitly NOT Recommended for Insomnia

Agents to Avoid

• Trazodone yields only ~10 minutes reduction in sleep latency and ~8 minutes reduction in wake after sleep onset, with no improvement in subjective sleep quality; adverse events occur in ~75% of older adults. 1
• Over-the-counter antihistamines (diphenhydramine, doxylamine) lack efficacy data, cause strong anticholinergic effects (confusion, urinary retention, falls, daytime sedation), and develop tolerance within 3–4 days. 1
• Traditional benzodiazepines (lorazepam, clonazepam, diazepam) have long half-lives leading to drug accumulation, prolonged daytime sedation, higher fall and cognitive-impairment risk, and associations with dementia and fractures. 1
• Antipsychotics (quetiapine, olanzapine) have weak evidence for insomnia benefit and significant risks (weight gain, metabolic dysregulation, extrapyramidal symptoms, increased mortality in elderly with dementia). 1
• Melatonin supplements produce only ~9 minutes reduction in sleep latency; evidence of efficacy is insufficient. 1

Common Pitfalls to Avoid

• Do not prescribe mirtazapine as first-line therapy without attempting CBT-I and FDA-approved hypnotics first; this violates guideline recommendations and bypasses more effective options. 1
• Do not use mirtazapine PRN (as needed); it requires consistent nightly dosing to maintain therapeutic blood levels (half-life 20–40 hours) and cannot provide immediate "on-demand" sedation like short-acting hypnotics. 1
• Do not combine mirtazapine with multiple sedating agents (e.g., adding a benzodiazepine or Z-drug), as this markedly increases the risk of respiratory depression, falls, cognitive impairment, and complex sleep behaviors. 1
• Do not continue mirtazapine long-term without periodic reassessment; efficacy may wane after 12 weeks, and tapering should be attempted while maintaining CBT-I support. 1, 4